A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048

BACKGROUND: MMV390048 is the first Plasmodium phosphatidylinositol 4-kinase inhibitor to reach clinical development as a new antimalarial. We aimed to characterize the safety, pharmacokinetics, and antimalarial activity of a tablet formulation of MMV390048. METHODS: A 2-part, phase 1 trial was condu...

Descripción completa

Detalles Bibliográficos
Autores principales: McCarthy, James S, Donini, Cristina, Chalon, Stephan, Woodford, John, Marquart, Louise, Collins, Katharine A, Rozenberg, Felix D, Fidock, David A, Cherkaoui-Rbati, Mohammed H, Gobeau, Nathalie, Möhrle, Jörg J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744986/
https://www.ncbi.nlm.nih.gov/pubmed/32239164
http://dx.doi.org/10.1093/cid/ciaa368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744986/
https://www.ncbi.nlm.nih.gov/pubmed/32239164
http://dx.doi.org/10.1093/cid/ciaa368

Ejemplares similares